The study aimed to assess how well angiopoietin-2 (Ang-2) can predict the outcomes of patients with acute respiratory distress syndrome (ARDS) over 60 days.
Researchers analyzed data from 132 ARDS patients, comparing their plasma Ang-2 levels and clinical outcomes to determine if high levels were linked to increased mortality.
Results indicated that higher plasma Ang-2 levels post-treatment were significantly associated with death within 60 days, identifying Ang-2 as an independent risk factor for poor prognosis in these patients.